SynthesisThe journals of gerontology. Series A, Biological sciences and medical sciences2018
Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies.
Synthesis in The journals of gerontology. Series A, Biological sciences and medical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting.Antioxidants (Basel, Switzerland) · 2026Review
- Genetic associations with longevity in a Calabrian cohort: an exploratory genome-wide study.GeroScience · 2026Article
- Article
- From 70 to 100: The Kuakini Hawaii Centenarian Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Article
- Race and ethnicity dynamics in survival to 100 years in the United States.Journal of internal medicine · 2025Article
- Multimodal Omics Approaches to Aging and Age-Related Diseases.Phenomics (Cham, Switzerland) · 2024Review
- The Biomarkers in Extreme Longevity: Insights Gained from Metabolomics and Proteomics.International journal of medical sciences · 2024Review
- Discovering Biological Mechanisms of Exceptional Human Health Span and Life Span.Cold Spring Harbor perspectives in medicine · 2023Review
- Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism.Clinical epigenetics · 2023Review
- Aging Hallmarks and the Role of Oxidative Stress.Antioxidants (Basel, Switzerland) · 2023Review
- FOXO3A-short is a novel regulator of non-oxidative glucose metabolism associated with human longevity.Aging cell · 2023Article
- A Genome-Wide Association Study of 2304 Extreme Longevity Cases Identifies Novel Longevity Variants.International journal of molecular sciences · 2022Article
- Optimizing Translational Research for Exceptional Health and Life Span: A Systematic Narrative of Studies to Identify Translatable Therapeutic Target(s) for Exceptional Health Span in Humans.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Protective Effects of Familial Longevity Decrease With Age and Become Negligible for Centenarians.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- New Directions in Research on Aging.Stem cell reviews and reports · 2022Article
- The 90 plus: longevity and COVID-19 survival.Molecular psychiatry · 2022Review
- Redox-mediated regulation of aging and healthspan by an evolutionarily conserved transcription factor HLH-2/Tcf3/E2A.Redox biology · 2020Article
- The genetics of human ageing.Nature reviews. Genetics · 2020Review
- Inflammaging in Endemic Areas for Infectious Diseases.Frontiers in immunology · 2020Review
- THE EXPOSOME IN HUMAN EVOLUTION: FROM DUST TO DIESEL.The Quarterly review of biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Previous studies note specific FOXO3 single-nucleotide polymorphisms (SNPs) associated with human longevity. However, it is not clear if these SNPs influence mortality risk beyond the oldest 1 percentile of survival. Using data from four longevity studies (total n = 8,266, age range 96-119 years for cases), we tested gene-wide association between 107 SNPs and survival to at least the oldest 1 percentile of survival for the 1900 birth cohort (≥96, white males; ≥100 white females). This analysis replicated 17 previously published variants, several of which are significant expression quantitative trait loci of FOXO3; rs6911407 and rs2253310 have the most significant effect on FOXO3 expressions in brain tissue. We then performed a survival analysis to determine if any of these 107 SNPs impact upon mortality risk beyond the oldest 1 percentile. While none of the 17 published variants was significantly associated with mortality risk beyond this extreme age, an uncommon homozygote genotype of rs9384680 exhibited the strongest association with mortality risk (p = 2.68E-04) in only 11 females, a heretofore unreported association. These analyses replicate the previous association of common variants of FOXO3 with older age but these common variants do not modify risk for mortality at ages beyond the oldest 1 percentile age of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.